CN118240006A - Cyclic tetrapeptides and compositions and uses thereof - Google Patents
Cyclic tetrapeptides and compositions and uses thereof Download PDFInfo
- Publication number
- CN118240006A CN118240006A CN202410236462.7A CN202410236462A CN118240006A CN 118240006 A CN118240006 A CN 118240006A CN 202410236462 A CN202410236462 A CN 202410236462A CN 118240006 A CN118240006 A CN 118240006A
- Authority
- CN
- China
- Prior art keywords
- agents
- acid
- stimulate
- salt
- synthesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- 125000004122 cyclic group Chemical group 0.000 title abstract description 26
- 102000001189 Cyclic Peptides Human genes 0.000 claims abstract description 63
- 108010069514 Cyclic Peptides Proteins 0.000 claims abstract description 63
- 150000003839 salts Chemical class 0.000 claims abstract description 38
- 238000002360 preparation method Methods 0.000 claims abstract description 23
- 108010065320 prolyl-lysyl-glutamyl-lysine Proteins 0.000 claims abstract description 9
- 210000004400 mucous membrane Anatomy 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 117
- 230000000694 effects Effects 0.000 claims description 70
- 102000003425 Tyrosinase Human genes 0.000 claims description 30
- 108060008724 Tyrosinase Proteins 0.000 claims description 30
- 230000015572 biosynthetic process Effects 0.000 claims description 30
- 238000003786 synthesis reaction Methods 0.000 claims description 30
- 108010003272 Hyaluronate lyase Proteins 0.000 claims description 25
- 102000001974 Hyaluronidases Human genes 0.000 claims description 25
- 229960002773 hyaluronidase Drugs 0.000 claims description 25
- 210000003491 skin Anatomy 0.000 claims description 24
- 102000016387 Pancreatic elastase Human genes 0.000 claims description 23
- 108010067372 Pancreatic elastase Proteins 0.000 claims description 23
- 230000002401 inhibitory effect Effects 0.000 claims description 23
- 230000005764 inhibitory process Effects 0.000 claims description 14
- -1 epidermohydrolases Substances 0.000 claims description 13
- 238000013268 sustained release Methods 0.000 claims description 13
- 239000012730 sustained-release form Substances 0.000 claims description 13
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims description 12
- 235000001014 amino acid Nutrition 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 9
- 230000002087 whitening effect Effects 0.000 claims description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 8
- 239000002537 cosmetic Substances 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 8
- 230000035755 proliferation Effects 0.000 claims description 8
- 102000016942 Elastin Human genes 0.000 claims description 7
- 108010014258 Elastin Proteins 0.000 claims description 7
- 210000001789 adipocyte Anatomy 0.000 claims description 7
- 229920002549 elastin Polymers 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 6
- 208000003351 Melanosis Diseases 0.000 claims description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- 210000002510 keratinocyte Anatomy 0.000 claims description 5
- 230000003020 moisturizing effect Effects 0.000 claims description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 239000002269 analeptic agent Substances 0.000 claims description 4
- 230000003712 anti-aging effect Effects 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 230000015556 catabolic process Effects 0.000 claims description 4
- 238000006731 degradation reaction Methods 0.000 claims description 4
- 230000004069 differentiation Effects 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 230000003779 hair growth Effects 0.000 claims description 4
- 230000035876 healing Effects 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 150000007522 mineralic acids Chemical class 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 230000008591 skin barrier function Effects 0.000 claims description 4
- 230000037394 skin elasticity Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- 208000012641 Pigmentation disease Diseases 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 210000002950 fibroblast Anatomy 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 210000002752 melanocyte Anatomy 0.000 claims description 3
- 230000003061 melanogenesis Effects 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 230000037393 skin firmness Effects 0.000 claims description 3
- 210000000434 stratum corneum Anatomy 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- NTQVODZUQIATFS-WAUHAFJUSA-N (2s)-2-[[(2s)-6-amino-2-[[2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-methylbutanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NTQVODZUQIATFS-WAUHAFJUSA-N 0.000 claims description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- 102000008490 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Human genes 0.000 claims description 2
- 108010020504 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Proteins 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- 239000002677 5-alpha reductase inhibitor Substances 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- 102000012440 Acetylcholinesterase Human genes 0.000 claims description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 claims description 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 108050001186 Chaperonin Cpn60 Proteins 0.000 claims description 2
- 102000052603 Chaperonins Human genes 0.000 claims description 2
- 108010009685 Cholinergic Receptors Proteins 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 230000033616 DNA repair Effects 0.000 claims description 2
- 102000004237 Decorin Human genes 0.000 claims description 2
- 108090000738 Decorin Proteins 0.000 claims description 2
- 102000000541 Defensins Human genes 0.000 claims description 2
- 108010002069 Defensins Proteins 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 2
- 102000016359 Fibronectins Human genes 0.000 claims description 2
- 108010067306 Fibronectins Proteins 0.000 claims description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 2
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 239000004909 Moisturizer Substances 0.000 claims description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 102000017946 PGC-1 Human genes 0.000 claims description 2
- 108700038399 PGC-1 Proteins 0.000 claims description 2
- 102000000536 PPAR gamma Human genes 0.000 claims description 2
- 108010016731 PPAR gamma Proteins 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 102000004079 Prolyl Hydroxylases Human genes 0.000 claims description 2
- 108010043005 Prolyl Hydroxylases Proteins 0.000 claims description 2
- 102100037132 Proteinase-activated receptor 2 Human genes 0.000 claims description 2
- 101710121435 Proteinase-activated receptor 2 Proteins 0.000 claims description 2
- 102000012479 Serine Proteases Human genes 0.000 claims description 2
- 108010022999 Serine Proteases Proteins 0.000 claims description 2
- 208000031439 Striae Distensae Diseases 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 102000034337 acetylcholine receptors Human genes 0.000 claims description 2
- 229940022698 acetylcholinesterase Drugs 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 230000002293 adipogenic effect Effects 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 claims description 2
- 238000004220 aggregation Methods 0.000 claims description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 229940035676 analgesics Drugs 0.000 claims description 2
- 229940035674 anesthetics Drugs 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 230000001139 anti-pruritic effect Effects 0.000 claims description 2
- 230000001153 anti-wrinkle effect Effects 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 229940125715 antihistaminic agent Drugs 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000003096 antiparasitic agent Substances 0.000 claims description 2
- 229940125687 antiparasitic agent Drugs 0.000 claims description 2
- 239000003213 antiperspirant Substances 0.000 claims description 2
- 239000003908 antipruritic agent Substances 0.000 claims description 2
- 229940030999 antipsoriatics Drugs 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 239000002249 anxiolytic agent Substances 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 150000001277 beta hydroxy acids Chemical class 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 229920001222 biopolymer Polymers 0.000 claims description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 2
- 239000004327 boric acid Substances 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 230000019522 cellular metabolic process Effects 0.000 claims description 2
- 229940106189 ceramide Drugs 0.000 claims description 2
- 150000001783 ceramides Chemical class 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 239000000812 cholinergic antagonist Substances 0.000 claims description 2
- 230000004087 circulation Effects 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 2
- 239000000975 dye Substances 0.000 claims description 2
- 230000002500 effect on skin Effects 0.000 claims description 2
- 239000003602 elastase inhibitor Substances 0.000 claims description 2
- 239000003974 emollient agent Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000011087 fumaric acid Nutrition 0.000 claims description 2
- 239000003193 general anesthetic agent Substances 0.000 claims description 2
- 239000000174 gluconic acid Substances 0.000 claims description 2
- 235000012208 gluconic acid Nutrition 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- 239000003410 keratolytic agent Substances 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 230000002366 lipolytic effect Effects 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 229920002521 macromolecule Polymers 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 claims description 2
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 claims description 2
- 239000000693 micelle Substances 0.000 claims description 2
- 239000004530 micro-emulsion Substances 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 230000004089 microcirculation Effects 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 230000001333 moisturizer Effects 0.000 claims description 2
- 230000004118 muscle contraction Effects 0.000 claims description 2
- 239000002088 nanocapsule Substances 0.000 claims description 2
- 239000007908 nanoemulsion Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 239000002077 nanosphere Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 235000021313 oleic acid Nutrition 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 230000003711 photoprotective effect Effects 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 239000000419 plant extract Substances 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000003380 propellant Substances 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 239000002516 radical scavenger Substances 0.000 claims description 2
- 210000002374 sebum Anatomy 0.000 claims description 2
- 239000000932 sedative agent Substances 0.000 claims description 2
- 229940125723 sedative agent Drugs 0.000 claims description 2
- 230000037307 sensitive skin Effects 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 230000000475 sunscreen effect Effects 0.000 claims description 2
- 239000000516 sunscreening agent Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 230000008728 vascular permeability Effects 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 239000000341 volatile oil Substances 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 208000010201 Exanthema Diseases 0.000 claims 1
- 229940123457 Free radical scavenger Drugs 0.000 claims 1
- 206010040829 Skin discolouration Diseases 0.000 claims 1
- 206010040925 Skin striae Diseases 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 12
- 229920001184 polypeptide Polymers 0.000 abstract description 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 19
- 239000011347 resin Substances 0.000 description 15
- 229920005989 resin Polymers 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 238000010168 coupling process Methods 0.000 description 9
- 238000005859 coupling reaction Methods 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 8
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 229920002385 Sodium hyaluronate Polymers 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000007974 sodium acetate buffer Substances 0.000 description 7
- 229940010747 sodium hyaluronate Drugs 0.000 description 7
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
- 230000000155 isotopic effect Effects 0.000 description 5
- 238000007363 ring formation reaction Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000037303 wrinkles Effects 0.000 description 5
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 206010014970 Ephelides Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 3
- 229960004705 kojic acid Drugs 0.000 description 3
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 3
- 230000008099 melanin synthesis Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 238000005086 pumping Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 206010008570 Chloasma Diseases 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- RVQDZELMXZRSSI-IUCAKERBSA-N Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 RVQDZELMXZRSSI-IUCAKERBSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000005808 skin problem Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 description 1
- OTKXCALUHMPIGM-FQEVSTJZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 OTKXCALUHMPIGM-FQEVSTJZSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- VQNDBXJTIJKJPV-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridine Chemical compound C1=CC=NC2=NNN=C21 VQNDBXJTIJKJPV-UHFFFAOYSA-N 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000030523 Catechol oxidase Human genes 0.000 description 1
- 108010031396 Catechol oxidase Proteins 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 101710147108 Tyrosinase inhibitor Proteins 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000002488 antieczema agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000010352 biotechnological method Methods 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- CEXCHYIGFUAPKW-UHFFFAOYSA-N methanol;piperidine Chemical compound OC.C1CCNCC1 CEXCHYIGFUAPKW-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229920000847 nonoxynol Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Abstract
Discloses a cyclic tetrapeptide, a composition and application thereof, and relates to the technical field of polypeptides, wherein the cyclic tetrapeptide has the following structure: cyclo- [ Pro-Lys-Glu-Lys ]. In particular to the cyclic peptides or salts thereof, or a composition thereof, and the use thereof in the preparation of a composition for caring for or treating skin or mucous membranes.
Description
Technical Field
The present disclosure relates to the field of polypeptide technology, and in particular to cyclic tetrapeptides, compositions thereof, and uses thereof.
Background
Tyrosinase (EC 1.14.18.1), also known as polyphenol oxidase, is a key rate-limiting enzyme that is widely found in organisms and catalyzes the synthesis of melanin. During melanogenesis, tyrosinase catalyzes the oxidation of L-tyrosine to L-dopa, which is subsequently oxidized to L-dopa quinone, which is then converted to melanin by a series of non-enzymatic reactions. In humans, tyrosinase is overexpressed, which may lead to pigmentation disorders such as age spots, freckles, chloasma, and melanoma. Meanwhile, tyrosinase activity was found to be associated with parkinson's disease and other neurodegenerative diseases in the mammalian brain. The tyrosinase activity can be inhibited to reduce the generation of skin melanin, so that the tyrosinase inhibitor has wide application prospects in the fields of cosmetics, health-care products and medicines.
The conventional tyrosinase inhibitors mainly comprise kojic acid, ascorbic acid, arbutin and the like, however, the inventor realizes that the tyrosinase inhibitors have certain defects, such as skin cancer caused by long-term use of the kojic acid, easy oxidation reaction of the ascorbic acid, high photosensitivity of the arbutin and poor stability of the three. The polypeptide has special physiological activity and can better improve certain problems of skin, and is a research and development hot spot in the fields of cosmetology and medicine in recent years. There are few types of polypeptides currently available for inhibiting tyrosinase activity, and there is still a great need in the marketplace.
Disclosure of Invention
The present disclosure relates to cyclic tetrapeptides and compositions and uses thereof, which have the effect of caring or treating skin or mucous membrane, and the like.
In one aspect, the present disclosure provides a cyclic peptide, or a stereoisomer thereof, or a mixture of its stereoisomers, or a salt thereof, having the structure Cyclo- [ Pro-Lys-Glu-Lys ].
The cyclic peptides of the present disclosure contain a large number of asymmetric carbon atoms, and those skilled in the art will appreciate that the cyclic peptides of the present disclosure have stereoisomers and may exist as stereoisomers or mixtures of stereoisomers and thus it is possible to obtain mixtures of isomers as well as racemic or diastereomeric mixtures, or pure diastereomers or enantiomers, depending on the number of asymmetric carbons and the isomers or isomeric mixtures present. In some embodiments, the cyclic peptides described in the present disclosure are pure isomers, i.e., enantiomers or diastereomers. In some embodiments, the structure of a cyclic peptide of the present disclosure is an L-isomer.
The present disclosure also includes all suitable isotopic variants of the cyclic peptide. Isotopic variations of the cyclic peptides of the present disclosure are understood herein to mean such compounds: wherein at least one atom is replaced with another atom of the same atomic number within the cyclic peptide of the present disclosure, but the atomic mass of the other atom is different from the atomic mass normally or predominantly present in nature. Examples of isotopes that can be incorporated into the cyclic peptides of the present disclosure are: those of hydrogen, carbon, nitrogen or oxygen, such as 2 H (deuterium), 3 H (tritium), 13C、14C、14N、15N、17 O or 18 O. Specific isotopic variants of the cyclic peptides of the present disclosure (particularly those into which one or more radioisotopes have been incorporated) may be advantageous, for example, for examining the mechanism of action or distribution of active compounds in vivo; cyclic peptides labeled with 3 H or 14 C isotopes are particularly suitable for this purpose due to their relatively simple producibility and detectability. In addition, due to the greater metabolic stability of cyclic peptides, the incorporation of isotopes (e.g., deuterium) may yield particular therapeutic benefits, such as increased in vivo half-life or reduced amounts of active agent required. Isotopic variants of the cyclic peptides of the present disclosure can be prepared by methods known to those skilled in the art, for example, by methods further described below and in the examples, by using the respective reagents and/or corresponding isotopic modifications of the starting materials.
The term "salt" refers to a salt that is approved for use in animals, and more specifically in humans, including metal salts of the cyclic peptides, including, but not limited to: lithium, sodium, potassium, calcium, magnesium, manganese, copper, zinc, or aluminum, etc.; including salts of the cyclic peptides with organic bases including, but not limited to: ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, arginine, lysine, histidine or piperazine and the like; including salts of the cyclic peptides with inorganic or organic acids including, but not limited to: acetic acid, citric acid, lactic acid, malonic acid, maleic acid, tartaric acid, fumaric acid, benzoic acid, aspartic acid, glutamic acid, succinic acid, oleic acid, trifluoroacetic acid, oxalic acid, pamoate (pamoate), gluconic acid, or the like; the inorganic acids include, but are not limited to: hydrochloric acid, sulfuric acid, boric acid or carbonic acid.
The nature of the salt is not critical and the salt of the cyclic peptide may be obtained by conventional methods well known in the art.
The synthesis of the cyclic peptides of the present disclosure, or stereoisomers thereof, or mixtures of stereoisomers thereof, or salts thereof, may be performed according to conventional methods known in the art, such as solid phase synthesis, liquid phase synthesis, or solid phase and liquid phase combination methods, and may also be prepared by biotechnological methods aimed at producing the desired sequence, or by controlled hydrolysis of proteins of animal, fungal, or plant origin.
For example, a method of obtaining a cyclic peptide of the present disclosure comprises the steps of:
-coupling an amino acid having a protected N-terminus and a free C-terminus with an amino acid having a free N-terminus and a protected or solid carrier-bound C-terminus;
-elimination of the group protecting the N-terminal end;
-repeating the coupling sequence and elimination of the N-terminal protecting group until the desired peptide sequence is obtained;
-elimination of the C-terminal protecting group or cleavage from the solid support;
-coupling and cyclizing the amino group at the N-terminus of the peptide chain with the carboxyl group at the C-terminus;
-elimination of the groups protecting the side chains.
In some embodiments, the C-terminus is bound to a solid support and the method is performed on a solid phase, comprising coupling an amino acid having a protected N-terminus and a free C-terminus to an amino acid having a free N-terminus and a C-terminus bound to a polymeric support; eliminating the group protecting the N-terminus; and repeating this sequence as many times as necessary to thereby obtain a peptide of the desired length, followed by cleavage of the synthesized peptide from the original polymer carrier and coupling cyclization of the amino group at the N-terminus of the peptide chain with the carboxyl group at the C-terminus.
The functional groups of the side chains of these amino acids remain fully protected throughout the synthesis with temporary or permanent protecting groups.
In some embodiments, solid phase synthesis can be performed by a pooling strategy (convergent strategy) of coupling a dipeptide or tripeptide to a polymeric support or to a dipeptide or amino acid previously bound to a polymeric support.
Due to application external to the body of a mammal, the cyclic peptides of the present disclosure may form part of various types of compositions. Thus in a further aspect of the present disclosure there is provided a composition comprising an effective amount of a cyclic peptide as described above, or a stereoisomer thereof, or a mixture of stereoisomers thereof, or a salt thereof, together with at least one excipient and optionally an adjuvant. The composition may be prepared by conventional methods known to those skilled in the art.
In some embodiments, the adjuvant is selected from the group consisting of: agents that activate Clock expression, analgesics, agents that inhibit PAR-2 activity, agents that modulate PGC-1 alpha synthesis, agents that modulate PPARgamma activity, agents that increase or decrease triglyceride levels in adipocytes, agents that stimulate or retard adipocyte differentiation, lipolytic or lipolysis-stimulating agents, lipolysates, adipogenic agents, inhibitors of acetylcholine receptor aggregation, agents that inhibit muscle contraction, anticholinergic agents, elastase inhibitors, matrix metalloproteinase inhibitors, melanin synthesis-stimulating or inhibiting agents, whitening or decolorizing agents, pigmentation-promoting agents, and, self-tanning agents, anti-aging agents, NO-synthase inhibitors, 5 alpha-reductase inhibitors, inhibitors of lysyl hydroxylase and/or prolyl hydroxylase, antioxidants, radical scavengers and/or anti-atmospheric agents, active carbonyl scavengers, anti-glycation agents, antihistamines, antiviral agents, antiparasitic agents, emulsifiers, emollients, organic solvents, liquid propellants, moisture retaining substances, alpha hydroxy acids, beta hydroxy acids, moisturizers, epidermohydrolases, vitamins, amino acids, proteins, pigments, dyes, biopolymers, gel polymers, thickeners, surfactants, softeners, adhesives, preservatives, Anti-wrinkle agents, agents capable of reducing or treating the lower pouch, keratolytic agents, antimicrobial agents, agents that stimulate the synthesis of dermal or epidermal macromolecules and/or that inhibit or prevent their degradation, agents that stimulate elastin synthesis, agents that stimulate decorin synthesis, agents that stimulate laminin synthesis, agents that stimulate defensin synthesis, agents that stimulate chaperonin synthesis, agents that stimulate cAMP synthesis, agents that stimulate hyaluronic acid synthesis, agents that stimulate fibronectin synthesis, agents that stimulate deacetylase synthesis, agents that stimulate the synthesis of lipids and stratum corneum components, ceramides, fatty acids, agents that inhibit elastin degradation, agents that inhibit serine proteases, Agents that stimulate fibroblast proliferation, agents that stimulate keratinocyte proliferation, agents that stimulate adipocyte proliferation, agents that stimulate melanocyte proliferation, agents that stimulate keratinocyte differentiation, agents that inhibit acetylcholinesterase, skin relaxants, agents that stimulate glycosaminoglycan synthesis, anti-hyperkeratosis agents, acne solubilizers, anti-psoriasis agents, anti-eczema agents, DNA repair agents, DNA protectants, stabilizers, antipruritics, agents for treating and/or caring for sensitive skin, solidifying agents, tightening agents, restructuring agents, stretch mark agents, sebum production regulating agents, antiperspirant agents, healing stimulating agents, healing assisting agents, re-epithelialization stimulating agents, Agents that assist re-epithelialization, cytokines, sedatives, anti-inflammatory agents, anesthetics, agents that act on capillary circulation and/or microcirculation, agents that stimulate angiogenesis, agents that inhibit vascular permeability, venous tone agents, agents that act on cellular metabolism, agents that improve dermis-epidermis junction, agents that induce hair growth, hair growth inhibition or delay agents, fragrances, chelators, plant extracts, essential oils, marine extracts, agents derived from biological fermentation processes, inorganic salts, cellular extracts, sunscreens, and organic or inorganic photoprotective agents that are effective against a and/or B uv light, or mixtures thereof.
The effective amount of the cyclic peptides of the present disclosure to be administered, as well as their dosage, will depend on a number of factors, including the age, the state of the user, the severity of the condition, the route and frequency of administration, and the particular nature of the cyclic peptide to be used.
By "effective amount" is meant an amount of a cyclic peptide of the present disclosure that is non-toxic but sufficient to provide the desired effect. The cyclic peptides of the present disclosure are used in compositions of the present disclosure at concentrations effective to achieve the desired effect. In some embodiments, the concentration is between 0.00000001% (by weight) and 20% (by weight) relative to the total weight of the composition; in some embodiments, the concentration is between 0.000001% (by weight) and 15% (by weight) relative to the total weight of the composition; in some embodiments, the concentration is between 0.0001% (by weight) and 10% (by weight) relative to the total weight of the composition; in some embodiments, the concentration is between 0.0001% (by weight) and 5% (by weight) relative to the total weight of the composition.
In another aspect of the present disclosure, a delivery system or a sustained release system is provided to achieve better penetration of an active ingredient comprising an effective amount of the cyclic peptide described above, or a stereoisomer thereof, or a mixture of stereoisomers thereof, or a salt thereof, or a composition of the above.
The term "delivery system" refers to a diluent, adjuvant, excipient, or carrier with which the cyclic peptides of the present disclosure are administered, selected from the group consisting of: water, oils or surfactants, including those of petroleum origin, animal origin, vegetable origin, or synthetic origin, such as, and not limited to, peanut oil, soybean oil, mineral oil, sesame oil, castor oil, polysorbates, sorbitan esters, ether sulfates, betaines, glucosides, maltosides, fatty alcohols, nonoxynol, poloxamers, polyoxyethylene, polyethylene glycols, dextrose, glycerol, digitonin, and the like. Diluents that may be used in different delivery systems to which the cyclic peptides of the present disclosure may be administered are known to those of ordinary skill in the art.
The term "sustained release" is used in a conventional sense to refer to a delivery system of a compound that provides gradual release of the compound over a period of time. In some embodiments, the sustained release system has a relatively constant level of compound release over a period of time.
Examples of delivery systems or sustained release systems include, but are not limited to: liposomes, oleosomes, ethosomes, millimeter capsules, microcapsules, nanocapsules, nanostructured lipid carriers, sponges, clathrates, lipid vesicles, micelles, millimeter spheres, microspheres, nanospheres, lipid spheres, microemulsions, nanoemulsions, millimeter particles, microparticles or nanoparticles.
In another aspect of the present disclosure, there is provided a cosmetic comprising an effective amount of the above cyclic peptide, or a stereoisomer thereof, or a mixture of stereoisomers thereof, or a salt thereof, or the above composition, or the above delivery system or sustained release system.
In some embodiments, the formulation of the cosmetic comprises a cream, an emulsion, a water, an oil, a gel, a powder, a tablet, a mud, a patch, a film, an aerosol, a spray, a lyophilized formulation, or a nano-formulation.
In another aspect of the present disclosure, there is provided a use of the above cyclic peptide, or a stereoisomer thereof, or a mixture of its stereoisomers, or a salt thereof, or the above composition, or the above delivery system or sustained release system, for the preparation of a composition for treating or treating skin or mucous membrane.
In another aspect of the present disclosure, there is provided a use of the above cyclic peptide, or a stereoisomer thereof, or a mixture of its stereoisomers, or a salt thereof, or the above composition, or the above delivery system or sustained release system, for the preparation of a composition for whitening, resolving macula, lightening skin color, or eliminating skin color non-uniformity.
In another aspect of the present disclosure, there is provided a use of the above cyclic peptide, or a stereoisomer thereof, or a mixture of its stereoisomers, or a salt thereof, or the above composition, or the above delivery system or sustained release system, for the preparation of a composition for inhibiting tyrosinase activity or inhibiting melanogenesis.
In another aspect of the present disclosure, there is provided a use of the above cyclic peptide, or a stereoisomer thereof, or a mixture of its stereoisomers, or a salt thereof, or the composition described above, or the delivery system or sustained release system described above, for the preparation of a composition for anti-aging, soothing, moisturizing or repairing.
In another aspect of the present disclosure, there is provided a use of the above cyclic peptide, or a stereoisomer thereof, or a mixture of its stereoisomers, or a salt thereof, or the above composition, or the above delivery system or sustained release system, for the preparation of a composition for inhibiting elastase activity, or for the preparation of a composition for increasing skin elasticity and/or improving skin firmness, or for the preparation of a composition for inhibiting hyaluronidase activity, or for the preparation of a composition for repairing skin barrier.
In another aspect of the present disclosure, there is provided a use of the above cyclic peptide, or a stereoisomer thereof, or a mixture of its stereoisomers, or a salt thereof, or the above composition, or the above delivery system or sustained release system, in the preparation of a cosmetic.
In this disclosure, the term "skin" is understood to be the layers that make up it, from the uppermost or stratum corneum to the lowermost or subcutaneous tissue, both endpoints being included. These layers are composed of different types of cells, such as keratinocytes, fibroblasts, melanocytes, and/or adipocytes, among others. In this disclosure, the term "skin" includes the scalp.
The term "care of the skin" refers to the maintenance and care of the skin, improving the condition of the skin, and making the skin delicate, smooth, tender and healthy.
The present disclosure has the following advantages and effects:
1. The cyclic peptides of the present disclosure are effective in inhibiting tyrosinase activity. Inhibiting tyrosinase activity can reduce melanin synthesis of organism, thereby achieving whitening and speckle-reducing effects. Therefore, the cyclic peptide disclosed by the invention can reduce melanin synthesis and has the effects of whitening and removing freckles.
2. The cyclic peptides of the present disclosure are effective in inhibiting elastase activity. Inhibition of elastase activity inhibits elastin hydrolysis and increases elastin levels in skin tissue, while loss of elastin is a major cause of skin aging leading to sagging, sagging and fine wrinkles. Therefore, the cyclic peptide disclosed by the invention can inhibit the activity of elastase, thereby being beneficial to increasing skin elasticity, improving skin firmness and removing skin wrinkles.
3. The cyclic peptides of the present disclosure are effective in inhibiting hyaluronidase activity. Inhibiting hyaluronidase activity can reduce decomposition of hyaluronic acid in cells, increase hyaluronic acid content level in cells, promote hydration of skin or mucosa, repair skin barrier, and has effects of moistening, relieving, and repairing. Therefore, the cyclopeptide disclosed by the invention can improve the content level of hyaluronic acid in cells, and has the effects of moisturizing, relieving and repairing.
4. The cyclic peptide disclosed by the invention is prepared by coupling and cyclizing the N-terminal and the C-terminal of tetrapeptide-30, but compared with linear tetrapeptide-30, the cyclic peptide disclosed by the invention has higher stability and transdermal property, has better effects of inhibiting tyrosinase activity, elastase activity and hyaluronidase activity, and effectively improves the effects of whitening, lightening spots, tightening, removing wrinkles, moisturizing, soothing and repairing.
Drawings
In order to more clearly illustrate the technical solutions of the present disclosure, the drawings that are needed in the description of the present disclosure will be briefly introduced below, and it is obvious that the drawings in the following description are only some embodiments of the present disclosure, and other drawings may be obtained according to these drawings without inventive effort to a person of ordinary skill in the art.
FIG. 1 is a mass spectrum of a cyclic tetrapeptide (formula C 22H38N6O6) of example 1 in the present disclosure.
FIG. 2 is a graph showing the results of tyrosinase activity assay experiments in example 2 of the present disclosure.
FIG. 3 is a graph showing the results of an elastase activity assay of example 3 of the present disclosure.
FIG. 4 is a graph showing the results of an experiment for measuring the hyaluronidase activity in example 4 of the present disclosure.
Detailed Description
In order that the manner in which the above recited objects, features and advantages of the present disclosure are obtained will become more readily apparent, a more particular description of the disclosure will be rendered by reference to the appended drawings and examples. It will be apparent that the described embodiments are some, but not all, of the embodiments of the present disclosure. Based on the embodiments in this disclosure, all other embodiments that may be obtained by one of ordinary skill in the art without inventive effort are within the scope of the claims appended hereto.
In the present disclosure, the abbreviations used for amino acids follow the rules specified by the IUPAC-IUB Biochemical nomenclature Commission (IUPAC-IUB Commission of Biochemical Nomenclature) in the European journal of biochemistry (Eur. J. Biochem.1984, 138:9-37).
Unless otherwise indicated, all reagents and materials used in the present disclosure are commercially available. The following are abbreviations for part of the reagents and materials:
2-CTC Resin: a starting resin for polypeptide synthesis; DMF: n, N-dimethylformamide; DCM: dichloromethane; DIPEA: diisopropylethylamine; meOH: methanol; piperidine: piperidine; HOBt: 1-hydroxybenzotriazole; DIC: diisopropylcarbodiimide; TFA: trifluoroacetic acid; PE: petroleum ether; HATU:2- (7-azabenzotriazol) -N, N' -tetramethylurea hexafluorophosphate; TIS: triisopropylsilane; lys: lysine; glu: glutamic acid; pro: proline; fmoc: 9-fluorenylmethoxycarbonyl; otBu: t-butoxy; boc: and tert-butoxycarbonyl group.
EXAMPLE 1 preparation of Cyclo- [ Pro-Lys-Glu-Lys ]
Cyclo- [ Pro-Lys-Glu-Lys ], prepared by the steps of:
S1 swelling of the resin
10G of 2-CTC Resin was weighed into a solid phase synthesis reaction column, swelled with DCM, the Resin washed, and the solvent was removed.
S2, feeding reaction
S2.1, 11.1g Fmoc-Lys (Boc) -OH, 9.7mL DIPEA were weighed into a dry flask. Dissolving with DMF solvent, adding into the swelled resin, reacting for 3h, pumping out the reaction solution, washing the resin, and pumping out the solvent. The capping treatments with DCM, meOH and DIPEA were continued for 30min. The resin was washed and the solvent was pumped away. Fmoc-Lys (Boc) -2-CTC Resin was obtained.
S2.2, fmoc-Lys (Boc) -2-CTC Resin was Fmoc-removed with 20% piperidine/DMF twice for 10min each time, sampled K for dark blue development. The resin was washed 7 times with DMF and the solvent was removed. 8.7g of Fmoc-Glu (OtBu) -OH and 3.5g of HOBt were weighed into a dry flask, dissolved in DMF and sealed in a-18℃refrigerator for 30min. Adding 4.7mLDIC to activate for 3min to avoid water vapor. And adding the activated amino acid into the deprotected resin to react for 1h, and pumping out the reaction solution. K detection resin is colorless and transparent, which indicates that the reaction is complete. Fmoc-Glu (OtBu) -Lys (Boc) -2-CTC Resin was obtained.
S2.3 deprotection of Fmoc group of Fmoc-Glu (OtBu) -Lys (Boc) -2-CTC Resin and coupling activated 9.6g Fmoc-Lys (Boc) -OH to the peptidyl Resin using DMF as solvent in the presence of 3.5g HOBt and 4.7mL DIC for 1h. These resins were then washed and the deprotection treatment of the Fmoc group was repeated to couple the next amino acid. The coupling was continued with 6.9g Fmoc-Pro-OH using DMF as solvent in the presence of 3.5g HOBt and 4.7mL DIC. After the reaction was completed, the resin was washed and the solvent was removed. Fmoc-Pro-Lys (Boc) -Glu (OtBu) -Lys (Boc) -2-CTC Resin was obtained.
S2.4, deprotection of Fmoc group of Fmoc-Pro-Lys (Boc) -Glu (OtBu) -Lys (Boc) -2-CTC Resin, removal of Fmoc with 20% piperidine/DMF was performed twice for 10min each time, sampling K and developing dark blue. The resin was washed 2 times with DMF and 5 times with DCM and the solvent was removed. After shrinkage drying, 18.0g of H-Pro-Lys (Boc) -Glu (OtBu) -Lys (Boc) -2-CTC Resin was obtained.
S3, resin removal
S3.1, measuring 144mL of 1% TFA/DCM, mixing and stirring uniformly to obtain a lysate for later use.
S3.2, taking 18g of H-Pro-Lys (Boc) -Glu (OtBu) -Lys (Boc) -2-CTC Resin, adding the Resin into a round bottom flask, adding the standby lysate, and carrying out cleavage reaction for 2 times each time for 0.5H. Suction filtration, collecting filtrate, concentrating to oily substance, adding PE, washing twice, soaking overnight, pouring out supernatant, and spin drying to obtain 11g oily H-Pro-Lys (Boc) -Glu (OtBu) -Lys (Boc) -OH total protective peptide.
S4, cyclization
S4.1, weighing 11g of H-Pro-Lys (Boc) -Glu (OtBu) -Lys (Boc) -OH full-protection peptide, 6.6g of HATU and 1.95g of HOBt, adding into a 250mL single-port bottle, adding 220mL of DMF, magnetically stirring, and adding 7.5g of DIPEA to make the reaction solution alkaline. The reaction was carried out overnight, and the reaction of the starting materials was complete by sampling HPLC.
S4.2, post-treatment: the reaction solution was centrifuged after ice-bath precipitation, washed with pure water for 4 times, and the solid portion was distilled with ethanol to obtain 5.9g of a crude cyclic peptide of Cyclo- [ Pro-Lys (Boc) -Glu (OtBu) -Lys (Boc) ] as a viscous solid.
S5 cleavage (deprotection group)
S5.1, measuring 33.63mL of TFA, 0.885mL of TIS and 0.885mL of water, mixing and stirring uniformly to obtain a lysate, sealing and placing in a refrigerator at-18 ℃ for later use; the isopropyl ether is placed in a refrigerator at the temperature of minus 18 ℃ for refrigeration for standby.
S5.2, 5.9g of Cyclo- [ Pro-Lys (Boc) -Glu (OtBu) -Lys (Boc) ] crude cyclic peptide was added to a round bottom flask, the above frozen lysate was added, and the reaction was stirred at 25℃for 2h. Suction filtration, collecting filtrate, adding 100mL isopropyl ether, stirring, centrifuging and washing for 4 times to obtain 5.2g of crude Cyclo- [ Pro-Lys-Glu-Lys ] cyclopeptide.
S6, purifying
5.2G of crude Cyclo- [ Pro-Lys-Glu-Lys ] cyclic peptide is taken, added with 80mL of pure water, dissolved completely by ultrasonic, filtered by a microporous filter membrane with the pore diameter of 0.45 μm to obtain a clear and transparent solution, and purified by reversed phase HPLC, the purification gradient is shown in the following table:
Time (min) | Flow rate (mL/min) | Mobile phase a-acetonitrile (%) | Mobile phase B-pure water (%) |
0 | 40 | 0.5 | 99.5 |
30 | 40 | 3 | 97 |
45 | 40 | 5 | 95 |
60 | 40 | 50 | 50 |
And (3) purifying the filtered sample, collecting fractions, concentrating and freeze-drying to obtain the Cyclo- [ Pro-Lys-Glu-Lys ] with the purity of 98.905 percent, which is marked as the cyclic tetrapeptide A. The molecular weight was 482.88 as determined by ESI-MS and the mass spectrum was shown in FIG. 1.
The linear peptide Pro-Lys-Glu-Lys (tetrapeptide-30) can be obtained by a similar preparation method.
EXAMPLE 2 tyrosinase activity assay
2.1 Reagents and materials
Mushroom tyrosinase, L-DOPA.
2.2 Instruments
An enzyme-labeled instrument and an ultra-clean workbench.
2.3 Samples to be tested and groupings
2.3.1 Sample to be tested
The concentrations of cyclic tetrapeptide A, tetrapeptide-30 and kojic acid were all 10ppm.
2.3.2 Grouping
Sample group: sample to be tested, tyrosinase, PBS and L-DOPA;
sample zeroing group: sample to be measured, PBS, L-DOPA;
blank control group: PBS, tyrosinase, L-DOPA;
Blank zeroing group: PBS, L-DOPA.
2.4 Experimental methods
Taking a 96-well plate, adding 50 mu L of a sample to be detected and 50 mu L of tyrosinase (25U/mL) into a sample group; adding 50 mu L of sample to be detected and 50 mu L of PBS into the sample zeroing group; a blank was added with 50. Mu. LPBS, 50. Mu.L tyrosinase (25U/mL); blank zeroing groups were added with 100 μ LPBS. After incubation at 37℃for 5min, 50. Mu. LPBS and 50. Mu.LL-DOPA (0.5 mmol/L) were added to each well and incubated at 37℃for 10min. OD 475 was measured at 475 nm.
Wherein: a 1 is the OD 475 value for the sample zeroed group, a 2 is the OD 475 value for the sample group, a 3 is the OD 475 value for the blank zeroed group, and a 4 is the OD 475 value for the blank control group.
2.5 Experimental results
L-DOPA is a substrate of tyrosinase, and is oxidized into black dopaquinone substances under the catalysis of tyrosinase, and absorbs visible light with a wavelength of 475 nm. The test samples are used for treating tyrosinase, and the reaction quantity of L-DOPA is detected to determine whether the cyclic tetrapeptide A can inhibit the activity of tyrosinase.
The effect of the test sample on tyrosinase activity inhibition is shown in fig. 2. The results show that the inhibition rate of the cyclic tetrapeptide A on the tyrosinase activity reaches 26.41%, and the inhibition rate of the tetrapeptide-30 on the tyrosinase activity is only 10.03%. The experimental result shows that the capability of inhibiting tyrosinase activity of the cyclic tetrapeptide A obtained by the head-tail cyclization of the tetrapeptide-30 is obviously improved compared with that of the linear tetrapeptide-30. From the results, the cyclic tetrapeptide A disclosed by the invention has excellent effect of inhibiting tyrosinase activity, can inhibit melanin generation, can be used for improving skin problems such as melanin precipitation and chloasma, and has the effects of whitening, removing freckles, brightening skin or eliminating uneven skin color.
Example 3 elastase Activity assay
3.1 Reagents and materials
PBS buffer, elastase solution, AAAPAN solution.
3.2 Instruments
An enzyme-labeled instrument and an electronic balance.
3.3 Samples to be tested and groupings
3.3.1 Sample to be tested
The concentrations of cyclic tetrapeptide A and tetrapeptide-30 were 200ppm.
3.3.2 Grouping
Sample group: sample to be tested, PBS, elastase, AAAPAN;
sample zeroing group: sample to be measured, PBS, AAAPAN;
blank control group: PBS, elastase, AAAPAN;
blank zeroing group: PBS, AAAPAN.
3.4 Experimental methods
Taking a 96-well plate, adding 85 mu L of PBS, 15 mu L of a sample to be tested and 25 mu L of elastase solution (2 mg/mL) into a sample group; adding 110 mu LPBS and 15 mu L of sample to be detected into the sample zeroing group; a blank group was added with 100. Mu. LPBS, 25. Mu.L elastase solution (2 mg/mL); blank zeroing groups were added with 125 μ LPBS. After incubation at 25℃for 15min, a further 25. Mu. LAAAPAN solution (1.015 mmol/L) was added to each well and incubated at 25℃for 15min. OD 410 was measured at 410 nm.
Wherein: a 1 is the OD 410 value for the sample zeroed group, a 2 is the OD 410 value for the sample group, a 3 is the OD 410 value for the blank zeroed group, and a 4 is the OD 410 value for the blank control group.
3.5 Experimental results
AAAPAN (N-succinyl-alanine-p-nitroaniline) is a substrate for elastase, AAAPAN is decomposed under the catalysis of elastase, and the decomposition product absorbs visible light with a wavelength of 410 nm. The test samples were used to treat elastase in this experiment to determine whether the cyclic tetrapeptide a of the present disclosure inhibited elastase activity by detecting the amount of reaction AAAPAN.
The effect of the test sample on inhibition of elastase activity is shown in FIG. 3. The result shows that the cyclic tetrapeptide A can obviously inhibit the activity of elastase, the inhibition rate of the cyclic tetrapeptide A of the present disclosure to the activity of the elastase reaches 48.1%, and the inhibition rate of the tetrapeptide-30 to the activity of the elastase is only 23.5%. The experimental result shows that the capability of the cyclic tetrapeptide A obtained by the head-tail cyclization of the tetrapeptide-30 for inhibiting the elastase activity is remarkably improved compared with that of the linear tetrapeptide-30. From the results, the cyclic tetrapeptide A disclosed by the invention has excellent effect of inhibiting elastase activity, can be used for improving skin problems such as skin relaxation and skin wrinkles, effectively increasing skin elasticity and/or improving skin compactness, and realizes the effects of resisting aging, tightening and removing wrinkles.
EXAMPLE 4 hyaluronidase Activity assay
4.1 Reagents and materials
Sodium acetate buffer (ph=5.6), hyaluronidase, calcium chloride, sodium hyaluronate, acetylacetone, absolute ethanol, sodium carbonate, P-DAB (P-dimethylaminobenzaldehyde (0.8 g) and concentrated hydrochloric acid (15 mL) and an equal amount of glacial acetic acid were homogeneously mixed to obtain the final product.
4.2 Instruments
An enzyme-labeled instrument and an electronic balance.
4.3 Samples to be tested and groupings
4.3.1 Sample to be tested
And the test concentrations of the cyclic tetrapeptide A and the tetrapeptide-30 are 100ppm and 200ppm.
4.3.2 Grouping
Sample group: a sample to be tested, hyaluronidase and sodium hyaluronate;
sample zeroing group: sample to be measured, sodium acetate buffer;
blank control group: distilled water, hyaluronidase, sodium hyaluronate;
Blank zeroing group: distilled water and sodium acetate buffer.
4.4 Experimental methods
Hyaluronidase and sodium hyaluronate are dissolved in sodium acetate buffer.
Taking a 96-well plate, adding 25 mu L of a sample to be detected and 25 mu L of hyaluronidase (1000U/mL) into a sample group; adding 25 mu L of sample to be detected and 25 mu L of sodium acetate buffer solution into the sample zeroing group; 25. Mu.L distilled water and 25. Mu.L hyaluronidase (1000U/mL) were added to the blank; the blank zeroing group was added with 25. Mu.L distilled water and 25. Mu.L sodium acetate buffer. After shaking for 20min at 37℃in a constant temperature gas bath, 5. Mu.L of calcium chloride solution (2.5 mol/L) was added to each well, and the mixture was shaken for 20min at 37℃in a constant temperature gas bath. 25 mu L of sodium hyaluronate (1 mg/mL) is added into the sample group and the blank control group, 25 mu L of sodium acetate buffer solution is added into the sample zeroing group and the blank zeroing group, and the mixture is placed at the constant temperature of 37 ℃ for shaking for 40min, and then is placed at the room temperature for 10min. Each well was further charged with 25. Mu.L of distilled water, 5. Mu.L of sodium hydroxide solution (5 mol/L), and 25. Mu.L of acetylacetone solution, and the mixture was placed in an oven at 90℃for 15min, further ice-bath for 10min, and finally at room temperature for 10min. 50. Mu.L of DAB was added to each well, followed by 100. Mu.L of absolute ethanol, and the mixture was left at room temperature for 30min and at 570nm to determine OD 570.
Wherein: a 1 is the OD 570 value for the sample zeroed group, a 2 is the OD 570 value for the sample group, a 3 is the OD 570 value for the blank zeroed group, and a 4 is the OD 570 value for the blank control group.
4.5 Experimental results
Sodium hyaluronate is a substrate of hyaluronidase, and is degraded under the catalysis of hyaluronidase to generate glucuronic acid and N-acetylglucosamine, and develops color under the action of P-DAB and absorbs visible light with 570nm wavelength. The present experiment employs a test sample to treat hyaluronidase, and the reaction amount of sodium hyaluronate is detected to determine whether the cyclic tetrapeptide A of the present disclosure can inhibit the activity of hyaluronidase.
The effect of the test sample on inhibition of hyaluronidase activity is shown in FIG. 4. The results show that the cyclic tetrapeptide a of the present disclosure can significantly inhibit the activity of hyaluronidase. At a concentration of 100ppm, the inhibition rate of the cyclic tetrapeptide A of the present disclosure on the hyaluronidase activity reaches 58.3%, while the inhibition rate of the tetrapeptide-30 on the hyaluronidase activity is only 37.7%. At a concentration of 200ppm, the inhibition rate of the cyclic tetrapeptide A of the present disclosure on the hyaluronidase activity reaches 62.6%, while the inhibition rate of the tetrapeptide-30 on the hyaluronidase activity is only 45.9%. The experimental result shows that the capability of the cyclic tetrapeptide A obtained by the head-tail cyclization of the tetrapeptide-30 for inhibiting the hyaluronidase activity is obviously improved compared with that of the linear tetrapeptide-30. From this, it can be seen that the cyclic tetrapeptide a of the present disclosure has an excellent effect of inhibiting hyaluronidase activity, can be used for repairing skin barrier, and has moisturizing, soothing and repairing effects.
Example 5
A whitening cream is prepared by the following steps:
Heating the D-phase material to 55-60 ℃ in a proper container according to the dosage of the prescription, and completely dissolving for standby; adding the phase A into a stirring pot, stirring and heating to 80-85 ℃; adding phase B into oil phase pot, stirring and heating to 75-80deg.C, completely dissolving and transparency; b phase is put into A phase, vacuum is started, homogenization is carried out for 5 minutes, stirring is maintained, and heat preservation is carried out for 20 minutes; cooling to 60-65deg.C, adding C phase and pre-dissolved D phase material, homogenizing for 2 min; cooling to 35-40deg.C, adding E phase material, and stirring for 10-15 min.
In this disclosure, relational terms such as first and second, and the like are used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Moreover, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or terminal that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or terminal. Without further limitation, an element defined by the phrase "comprising one … …" does not exclude the presence of other like elements in a process, method, article, or terminal device that comprises the element.
Although specific embodiments of the disclosure have been described for illustrative purposes, various modifications or improvements can be made by those skilled in the art without departing from the spirit and scope of the disclosure. Such variations and modifications are intended to fall within the scope of the claims appended hereto.
Claims (13)
1. A cyclic peptide or a salt thereof, wherein the cyclic peptide has a structure of Cyclo- [ Pro-Lys-Glu-Lys ].
2. The cyclic peptide or salt thereof according to claim 1, wherein the salt comprises a metal salt of the cyclic peptide, the metal comprising: lithium, sodium, potassium, calcium, magnesium, manganese, copper, zinc or aluminum;
or the salt comprises a salt of the cyclic peptide with an organic base comprising: ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, arginine, lysine, histidine or piperazine;
Or the salt comprises a salt of the cyclic peptide with an inorganic acid or an organic acid comprising: acetic acid, citric acid, lactic acid, malonic acid, maleic acid, tartaric acid, fumaric acid, benzoic acid, aspartic acid, glutamic acid, succinic acid, oleic acid, trifluoroacetic acid, oxalic acid, pamoic acid or gluconic acid; the inorganic acid includes: hydrochloric acid, sulfuric acid, boric acid or carbonic acid.
3. A composition comprising an effective amount of a cyclic peptide or salt thereof according to claim 1 or 2, together with at least one excipient and optionally an adjuvant.
4. A composition according to claim 3, wherein the adjuvant is selected from the group consisting of: agents that activate Clock expression, analgesics, agents that inhibit PAR-2 activity, agents that modulate PGC-1 alpha synthesis, agents that modulate PPARgamma activity, agents that increase or decrease triglyceride levels in adipocytes, agents that stimulate or retard adipocyte differentiation, lipolytic or lipolysis-stimulating agents, lipolysates, adipogenic agents, inhibitors of acetylcholine receptor aggregation, agents that inhibit muscle contraction, anticholinergic agents, elastase inhibitors, matrix metalloproteinase inhibitors, melanin synthesis-stimulating or inhibiting agents, whitening or decolorizing agents, Pigmentation-promoting agents, self-tanning agents, anti-ageing agents, NO-synthase inhibitors, 5 alpha-reductase inhibitors, inhibitors of lysyl hydroxylase and/or prolyl hydroxylase, antioxidants, free radical scavengers and/or agents against atmospheric pollution, active carbonyl scavengers, anti-glycation agents, antihistamines, antiviral agents, antiparasitic agents, emulsifiers, emollients, organic solvents, liquid propellants, moisture-retaining substances, alpha hydroxy acids, beta hydroxy acids, moisturizers, epidermohydrolases, vitamins, amino acids, proteins, pigments, dyes, biopolymers, gelling polymers, thickeners, surfactants, softeners, Adhesives, preservatives, anti-wrinkle agents, agents capable of reducing or treating the lower pouch, keratolytic agents, antimicrobial agents, agents that stimulate the synthesis of dermal or epidermal macromolecules and/or that inhibit or prevent their degradation, agents that stimulate elastin synthesis, agents that stimulate decorin synthesis, agents that stimulate laminin synthesis, agents that stimulate defensin synthesis, agents that stimulate chaperonin synthesis, agents that stimulate cAMP synthesis, agents that stimulate hyaluronic acid synthesis, agents that stimulate fibronectin synthesis, agents that stimulate deacetylase synthesis, agents that stimulate the synthesis of lipids and stratum corneum components, ceramides, fatty acids, agents that inhibit elastin degradation, Agents that inhibit serine proteases, agents that stimulate fibroblast proliferation, agents that stimulate keratinocyte proliferation, agents that stimulate adipocyte proliferation, agents that stimulate melanocyte proliferation, agents that stimulate keratinocyte differentiation, agents that inhibit acetylcholinesterase, skin relaxants, agents that stimulate glycosaminoglycan synthesis, anti-hyperkeratosis agents, acne solubilizers, anti-psoriasis agents, anti-rash agents, DNA repair agents, DNA protectants, stabilizers, antipruritics, agents for treating and/or caring for sensitive skin, solidifying agents, tightening agents, restructuring agents, anti-stretch marks agents, agents that regulate sebum production, antiperspirant agents, agents that stimulate healing, agents that assist healing, agents that stimulate re-epithelialization, agents that assist re-epithelialization, cytokines, sedatives, anti-inflammatory agents, anesthetics, agents that act on capillary circulation and/or microcirculation, agents that stimulate angiogenesis, agents that inhibit vascular permeability, venous tone agents, agents that act on cellular metabolism, agents that improve dermal-epidermal junction, agents that induce hair growth, hair growth inhibition or delay agents, fragrances, chelating agents, plant extracts, essential oils, marine extracts, agents derived from biological fermentation processes, inorganic salts, cell extracts, sunscreens, and organic or inorganic photoprotective agents that are effective against a and/or B ultraviolet light, or mixtures thereof.
5. A delivery system or sustained release system comprising an effective amount of the cyclic peptide or salt thereof of claim 1 or 2, or the composition of claim 3 or 4;
The delivery system or sustained release system comprises: liposomes, oleosomes, ethosomes, millimeter capsules, microcapsules, nanocapsules, nanostructured lipid carriers, sponges, clathrates, lipid vesicles, micelles, millimeter spheres, microspheres, nanospheres, lipid spheres, microemulsions, nanoemulsions, millimeter particles, microparticles or nanoparticles.
6. Cosmetic product, characterized in that it comprises an effective amount of a cyclic peptide or a salt thereof according to claim 1 or 2, or a composition according to claim 3 or 4, or a delivery system or a slow release system according to claim 5.
7. The cosmetic product according to claim 6, wherein the formulation of the cosmetic product comprises a cream, an emulsion, an aqueous solution, an oil, a gel, a powder, a tablet, a mud, a patch, a film, an aerosol, a spray, a lyophilized preparation or a nano-preparation.
8. Use of a cyclic peptide or a salt thereof according to claim 1 or 2, or a composition according to claim 3 or 4, or a delivery system or a slow release system according to claim 5, for the preparation of a composition for the care or treatment of skin or mucous membranes.
9. Use of a cyclic peptide or a salt thereof according to claim 1 or 2, or a composition according to claim 3 or 4, or a delivery system or a slow release system according to claim 5 for the preparation of a composition for whitening, freckle removing, skin lightening or skin colour non-uniformity eliminating.
10. Use of a cyclic peptide or a salt thereof according to claim 1 or 2, or a composition according to claim 3 or 4, or a delivery system or a slow release system according to claim 5 for the preparation of a composition for inhibiting tyrosinase activity or inhibiting melanogenesis.
11. Use of a cyclic peptide or a salt thereof according to claim 1 or 2, or a composition according to claim 3 or 4, or a delivery system or a slow release system according to claim 5, for the preparation of a composition for anti-ageing, soothing, moisturizing or repairing.
12. Use of a cyclic peptide or a salt thereof according to claim 1 or 2, or a composition according to claim 3 or 4, or a delivery system or a slow release system according to claim 5, for the preparation of a composition for inhibiting elastase activity, or for the preparation of a composition for increasing skin elasticity and/or improving skin firmness, or for the preparation of a composition for inhibiting hyaluronidase activity, or for the preparation of a composition for repairing skin barrier.
13. Use of a cyclic peptide or a salt thereof according to claim 1 or 2, or a composition according to claim 3 or 4, or a delivery system or a slow release system according to claim 5 for the preparation of a cosmetic.
Publications (1)
Publication Number | Publication Date |
---|---|
CN118240006A true CN118240006A (en) | 2024-06-25 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2408801B1 (en) | Peptides for use in cosmetic or pharmaceutical treatment of the skin, mucous membranes and/or scalp | |
EP2331560B1 (en) | Peptides useful in the treatment and/or care of skin, mucous membranes, scalp and/or hair and their use in cosmetic or pharmaceutical compositions | |
AU2010237349B2 (en) | Peptides used in the treatment and/or care of the skin and/or hair and their use in cosmetic or pharmaceutical compositions | |
CN115594735B (en) | Peptides with anti-aging effect, compositions and uses thereof | |
BR112012009264A2 (en) | GENERAL FORMULA PEPTIDE (I) AND PHARMACEUTICAL OR COSMETIC COMPOSITION | |
AU2011264125A1 (en) | Skin antiaging treatment | |
CN114315960A (en) | Modified peptide, and cosmetic composition or medicinal composition and application thereof | |
CN117106021B (en) | Hexapeptides, compositions and uses thereof | |
CN116284241B (en) | Peptides, compositions and uses thereof | |
CN117106023B (en) | Pentapeptide compounds, compositions and uses thereof | |
CN114315968A (en) | Nonapeptide, and cosmetic composition or medicinal composition and application thereof | |
CN117126242B (en) | Heptapeptides, compositions and uses thereof | |
CN118240006A (en) | Cyclic tetrapeptides and compositions and uses thereof | |
CN118206619A (en) | Cyclic nonapeptides, compositions and uses thereof | |
CN117304265B (en) | Skin care polypeptide, composition and application thereof | |
CN117402216B (en) | Octapeptide, and composition and use thereof | |
CN118146299A (en) | Cyclic peptides and compositions and uses thereof | |
CN117106022B (en) | Heptapeptide compounds, compositions and uses thereof | |
CN117304266B (en) | Skin treatment polypeptide, composition and application thereof | |
WO2023077339A1 (en) | Tetrapeptide derivative, cosmetic composition or pharmaceutical composition and use thereof | |
CN117417408B (en) | Anti-aging hexapeptide, composition and application thereof | |
CN118063547A (en) | Cyclic octapeptide and compositions and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication |